The A*STAR Computational Resource Centre (A*CRC) is a user facility which provides supercomputing resources for the A*STAR research community.

The Centre offers:

• Compute resource on multiple operating platforms to support a full spectrum of users
• A comprehensive range of third-party software for a diverse span of applications
• A friendly and informative web portal
• Regular roadshows for outreach and feedback sessions
• Highly-trained HPC support staff for administration and optimization of compute resource
• Network storage technologies

BII was established in July 2001 to train manpower and build capabilities in bioinformatics. BII's research focus centres around knowledge discovery from biological data, exploiting high-end computing in biomedicine, advancing molecular imaging of biological processes, modelling of drug design and delivery, computational proteomics and systems biology.

The mission of the Bioprocessing Technology Institute (BTI) is to develop manpower capabilities and establish cutting-edge technologies relevant to the bioprocess community. Spearheading bioprocess R&D, the BTI has core expertise in expression engineering, animal cell technology, stem cells, microbial fermentation, product characterisation, downstream processing, purification and stability, with supporting proteomics and microarray platform technologies. BTI, with its R&D and its cGMP manufacturing capabilities, bridges the gaps between discovery, process development and commercialisation.

Research undertaken by DSI include:

• Magnetic head materials and design
• Microsystems and nanosystems for data storage
• Signal processing for data storage and communications
• Tribology and tribochemistry, failure analysis
• Nano spin-electronics
• Optical storage technologies
• Laser nanoprocessing
• Network storage technologies

Established in June 2000 as the Singapore Genomics Program, the renamed Genome Institute of Singapore (GIS) is a national flagship initiative with a global vision that seeks to use genomic sciences to improve public health and prosperity.
As a centre for genomic discovery, GIS pursues the integration of technology, genetics, and biology towards the goal of individualised medicine. The scientific focus will be to investigate post-sequence genomics; to understand the genetic architecture of pan-Asian populations with emphasis on cancer biology, pharmacogenomics, stem cell biology and infectious diseases. The genomics infrastructure at GIS will be utilized to train new scientific talent, to function as a bridge for academic and industrial research and explore scientific questions of high impact.
Dr Edison Liu, former Director of the National Cancer Institute's Division of Clinical Sciences in the U.S.A., heads the GIS as the Executive Director.

I²R performs R&D in information, communications and media (ICM) technologies to develop holistic solutions across the ICM value chain. Our research capabilities are in information technology, wireless and optical communication networks, interactive and digital media; signal processing and computing.

The following are our research departments and programs:

Departments:

• Communication Systems
• Computer Graphics and Interface
• Computer Vision and Image Understanding
• Cryptography and Security
• Data Mining
• Human Language Technology
• Modulation and Coding
• Network Protocols
• RF and Optical
• Signal Processing

Programmes:

• Assistive ICT Systems for Monitoring and Rehabilitation for the Elderly
• High Speed Maritime Mesh Networks
• Next Generation Content for IPTV
• Personal 3D Entertainment Systems
• Power-aware Wireless Sensor Network for Tracking and Monitoring
• Towards Gigabit Personal Connectivity

Since 2003, the Institute of Bioengineering and Nanotechnology has carved out a unique niche at the interface of bioengineering and nanotechnology with its impactful research. Led by Executive Director Professor Jackie Y. Ying, the Institute’s multidisciplinary research teams have contributed to advancements in science, engineering and medicine by generating new knowledge and creating innovative materials, devices, processes and tools to transform healthcare and medical technologies.

• Drug and Gene Delivery - where the controlled release of therapeutics involves the use of functionalized polymers, hydrogels and biologics for targeting diseased cells and organs, and for responding to specific biological stimuli.

• Cell and Tissue Engineering - where biomimicking materials, stem cell technology, microfluidic systems, and bioimaging tools are combined to develop novel approaches to regenerative medicine and artificial organs.

• Biosensors and Biodevices - which involve nanotechnology and microfabricated platforms for high-throughput biomarkers screening, automated biologics synthesis, and rapid disease diagnosis.

• Pharmaceuticals Synthesis and Nanobiotechnology - which encompass the efficient catalytic synthesis of chiral pharmaceuticals, and new nanocomposite materials for sustainable technology and alternative energy generation.

ICES spearheads R&D in Singapore's fast expanding chemical industry. Established in October 2002, our mission is to carry out world class scientific research, to develop novel technology and to nurture creative scientists and engineers to support economic growth in Singapore and to make a positive difference to society. The research programmes cover chemistry and chemical engineering sciences, combined with analytical characterisation and measurement to develop advanced technology for the petrochemical, general chemical, fine chemical and pharmaceutical industries.

The focus of our research is in the areas of:

• Drug discovery & natural product synthesis
• Pharmaceutical processing
• Novel processes & materials for specialty products
• Energy/fuels/chemicals from alternative & renewable feed stocks
• Bulk chemicals & polymers

Research undertaken by IHPC include:

• Continuum methods in modeling and simulation
• Nanomechanics
• Solid and fluid mechanics
• Computational chemistry
• Atomistics and molecular dynamics modeling

Research undertaken by IMRE include:

• Polymer science and chemistry
• Nanomaterials
• Advanced materials characterization
• Performance materials
• Nanoparticles
• Macromolecular chemistry
• Surface science

The Institute of Medical Biology (IMB) has a strategic, programme-directed portfolio of research focused on issues at the critical interface between basic science and medicine. The aim is to facilitate the development of translational research by building bridges between clinical and basic science. IMB is currently hosting research programmes concerned with different aspects of human disease.

The current programmes within IMB are the Singapore Onco-Genome project, Regenerative Medicine, Papillomavirology, Epithelial Biology and the Lab of Stem Cell Biology from Singapore Stem Cell Consortium (SSCC). The Institute of Medical Biology will help scientists and clinicians to work closely together to support, inform and refine each other’s strengths and specializations to increase the efficiency of the translation process, and ultimately contribute towards a better quality of life for all.

Recent R&D efforts include:

• 3-10 GHz CMOS pulse-based UWB chip
• 90 nm RF device modeling
• Nanoscale CMOS incorporating new materials and structures with emphasis on RF performance
• Wafer Transfer Technology for multi-functional integration
• Si based bio-electronic devices / sensors and Si / SiGe based optoelectronics
• DNA /RNA extraction and amplification chips
• Fluidic self assembly processes
• Off chip nano interconnects
• RF front end module and CWDM / burst mode transceivers integration using System in Package approach 
  

The Institute of Molecular and Cell Biology (IMCB) was established in 1987 to help develop and support biomedical R&D capabilities in Singapore. Currently the institute has 34 independent research groups with more than 400 staff members.

Today, IMCB has established itself as a world-class research institute in biomedical sciences with core strengths in cell cycling, cell signaling, cell death, cell motility and protein trafficking. Its recent achievements include being part of an international consortium which successfully sequenced the entire pufferfish (Fugu) genome - a world first. IMCB was awarded the Nikkei Prize 2000 for Technological Innovation in recognition of its growth into a leading international research centre and its collaboration with industry and research institutes world-wide.

Established in 1975, the National Metrology Centre (NMC) is Singapore's national measurement authority. It is responsible for establishing, maintaining and disseminating the national physical measurement standards to underpin the nation's infrastructure for traceability of measurement to the International System of Units (SI).  Since 1 January 2008, the National Metrology Centre (NMC) has been transferred from SPRING Singapore to A*STAR.

The SERC Nanofabrication and Characterisation (SNFC) facility aims to make A*STAR's Science and Engineering Research Council's (SERC) extensive research facilities in Nanofabrication and Characterization technology accessible to the research community. The facility provides easy access to a wide range of research facilities and expertise on a variety of materials. SNFC also offers training courses for new and inexperienced users as well as consultancy and service work on baseline processes and characterizations.

SINERGY (Singapore Initiative in New Energy Technologies) Centre is a national level infrastructure for the R&D, testbedding and demonstration of sustainable energy technologies and solutions. It will conduct research, development and demonstration of new and innovative energy technologies both through its in-house activities and projects, as well as other collaborators in academia, government and industry. It will support and provide evaluation, system integration, test-bedding and other services for innovations and technologies from research programmes, working with industry and government agencies to support their successful introduction and commercialisation in the marketplace.

SINERGY Centre will comprise two main facilities:

1. Microgrid and Distributed Energy Test Facility – This will enable researchers and companies to test-bed novel power generating, storage, and integrated power/ thermal systems and study their performance in a microgrid environment, utilising a variety of conventional and alternative fuels such as natural gas, biofuels and hydrogen.

2. Command & Control Facility - This will serve as the control centre for the assets on the microgrid and also provide access to other systems and assets operated by collaborators both in Singapore and worldwide. The facility will have technology to enable real-time information exchange, remote and intelligent monitoring, diagnosis, decision-making, control and management. Such capabilities are important for the operation of physical energy and power systems; and for complex energy markets.

The Singapore Institute for Clinical Sciences (SICS) will accelerate the translation of basic discoveries into new diagnostics and therapeutics.  SICS will be distinguished by its focus on clinical science and the use of innovative approaches and technologies that enable the efficient and effective study of human health and disease. In so doing, the institute will attract, train and nurture a new type of clinician scientist.  SICS will collaborate with universities, research institutes and clinical programs to achieve the ultimate goal of improving human health as well as Singapore’s economic well-being.

The research focus of SICS will be centered on the human as the model system, and will complement other A*STAR Research Institutes by focusing on the clinical and translational research portion of the spectrum of biomedical research.  SICS will have both intramural research programs and extramural outreach initiatives.
 
Intramural Programs are focused on specific disease areas.  The initial programs at SICS are Genetic Medicine, Hepatic Infectious Diseases andMetabolic Diseases. SICS participates in, or provides oversight to programs external to our institute through our Extramural Programs: Lilly-NUS/SICS Joint Fellowship, Metabolic Interest Group, Supporting the National Medical Research Council in coordinating the STaR Investigatorship Awards and Translational and Clinical Research Flagship Awards
 

SIMTech, the research institute in manufacturing technology, is committed to enhancing the competitiveness of Singapore's industries through the generation and application of advanced manufacturing technology. Its areas of research focus include Production and Logistics, Advanced Forming and Joining Technology, Machining Technology, Mechatronics, Precision Measurement, Advanced Automation and Product Design and Development.

Research undertaken by SIMTech include:

• Advanced automation systems
• Control systems
• Precision metrology
• Robotics control systems
• Mechatronics, systems engineering
• Micro-manipulation technologies
• Laser processing and design
• Photonics
• Optics
• Product development life cycle management
• Artificial intelligence applications
• Materials processing casting technologies
• Supply chain methods
• Operations research

The Chemical Synthesis Laboratory @ Biopolis extends the current capabilities of the Institute of Chemical & Engineering Sciences (ICES) and complements its chemicals and pharmaceuticals research and development scope from discovery, to development and manufacture of products.
CSL@Biopolis is led by its Programme Director, Professor Kyriacos Costa (K.C.) Nicolaou, Chairman of the Department of Chemistry, the Skaggs Professor of Chemical Biology, and the Darlene Shiley Chair in Chemistry at The Scripps Research Institute and also Professor of Chemistry at the University of California, San Diego.